Glucagen

Glucagen is a prescription injectable solution that contains the peptide hormone glucagon as its active ingredient. It is supplied in an unspecified strength and is administered by intramuscular, intravenous, or subcutaneous injection. Marketed in the European Union, Glucagen belongs to the antihypoglycemic therapeutic class and is used to rapidly raise blood glucose levels in emergency situations. It is intended for use under medical supervision and is prescription‑only.

Glucagen is indicated for specific acute medical conditions where rapid elevation of blood glucose is required.

- Treatment of severe hypoglycemia in patients with diabetes when oral glucose is ineffective or unavailable. - Emergency management of hypoglycemia in unconscious or unable-to‑swallow individuals. - Reversal of beta‑blocker or calcium‑channel blocker overdose when conventional therapies are insufficient. - Use as a diagnostic aid in certain endocrine testing protocols.

The safety profile of Glucagen reflects the pharmacologic actions of glucagon and the route of administration.

Common: - Nausea or vomiting - Flushing or warmth at the injection site - Transient headache - Mild abdominal discomfort

Serious: - Severe allergic reaction (anaphylaxis) with rash, itching, swelling, or difficulty breathing - Rapid heart rate (tachycardia) or irregular heartbeat - Persistent high blood pressure - Hypersensitivity leading to angioedema

Healthcare providers should consider several precautions before prescribing or administering Glucagen to ensure patient safety.

- Verify the patient’s diagnosis of hypoglycemia and assess for possible glucagon contraindications. - Use caution in patients with pheochromocytoma or adrenal medullary tumors due to potential hypertensive response. - Monitor cardiovascular status in individuals with known heart disease, as glucagon can increase heart rate and contractility. - Adjust dosing in pediatric patients according to weight‑based guidelines and clinical response. - Avoid use in patients with known hypersensitivity to glucagon or any formulation components. - Ensure proper storage away from light and at recommended temperature to maintain potency.

Glucagen may interact with other medications or substances, influencing its effectiveness or safety.

Avoid: - Concurrent use of beta‑blockers that may mask typical glucagon‑induced tachycardia. - Combination with insulin analogs administered shortly before glucagon, which can exacerbate glucose fluctuations.

Use with caution: - Anticholinergic agents, as they may affect gastrointestinal motility and absorption of glucose. - Calcium‑channel blockers, because combined cardiovascular effects may require monitoring. - MAO inhibitors, which could alter autonomic responses during hypoglycemia treatment.